Inactive Instrument

Opsens Inc.

Equities

OPS

CA6838231083

Advanced Medical Equipment & Technology

OpSens Inc Appoints Brad Davis as Chief Commercial Officer

February 09, 2022 at 07:00 am EST

OpSens Inc. announced that Brad Davis will assume the role of Chief Commercial Officer and head a leadership team responsible for global commercialization and expanding U.S. commercial operations. He will report to Louis Laflamme, OpSens President and CEO. Brad Davis formerly served as Vice President, Global Marketing and Health Care Economics & Reimbursement at Cardiovascular Systems Inc. (CSI).

During his nearly seven-year tenure at CSI, the company tripled coronary atherectomy revenue and grew peripheral atherectomy revenue faster than market to achieve U.S.

Latest news about Opsens Inc.

Haemonetics Completes $255 Million Acquisition of OpSens	Dec. 12	MT
OpSens Brief: NYSE's Haemonetics Completed Acquisition	Dec. 12	MT
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).	Dec. 11	CI
OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics	Dec. 08	MT
OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics	Dec. 08	MT
Opsens Shareholders Approve Arrangement With Haemonetics	Dec. 01	MT
Transcript : Opsens Inc. - Shareholder/Analyst Call	Dec. 01
OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied	Nov. 28	MT
Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Nov. 22	CI
OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics	Nov. 22	MT
Opsens Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	Nov. 21	CI
OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics	Nov. 13	MT
Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens	23-10-11	MT
Needham on Opsens Being Acquired by Haemonetics	23-10-11	MT
Toronto Stocks Advance; Opsens Soars on C$345 Million Buyout Deal	23-10-10	DJ
OpSens Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics	23-10-10	MT
Haemonetics to Acquire OpSens for $253 Million in Cash	23-10-10	MT
OpSens Brief: Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics	23-10-10	MT
Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million.	23-10-09	CI
Transcript : Opsens Inc., Q3 2023 Earnings Call, Jul 13, 2023	23-07-13
Opsens Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-13	CI
OpSens Reports Q3 Consolidated Revenue of $13.2 Million; Net Loss of $0.04 Per Diluted Share	23-07-13	MT
OpSens Brief: Q3 Consolidated revenues of $13.2 million, compared with $10.1 million in the third quarter of 2022	23-07-13	MT
North American Morning Briefing : Optimism Set to Continue as Focus Shifts to Earnings	23-07-13	DJ
OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study	23-05-10	CI

Chart Opsens Inc.

Duration

Period

More charts

Company Profile

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Companyâs segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+11.73%	226B
DANAHER CORPORATION	+9.53%	188B
INTUITIVE SURGICAL, INC.	+14.63%	137B
BOSTON SCIENTIFIC CORPORATION	+27.47%	108B
SIEMENS HEALTHINEERS AG	-0.04%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+13.73%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.72%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+7.86%	38.07B

Other Advanced Medical Equipment & Technology